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Patients Aged 70 Years or Older
Yuh-Min Chen, MD, PhD, FCCP,*†‡ Chun-Ming Tsai, MD,* Wen-Chien Fan, MD,§
Jen-Fu Shih, MD,* Shih-Hao Liu, MD, Chieh-Hung Wu, MD,* Teh-Ying Chou, MD, PhD,
Yu-Chin Lee, MD,* Reury-Perng Perng, MD, PhD,* and Jacqueline Whang-Peng, MD‡
Introduction: The primary objective of this study was to compare
the response rates of elderly, chemonaive patients with advanced
non-small cell lung cancer (NSCLC) treated with daily oral erlotinib
versus oral vinorelbine.
Methods: Chemonaive Taiwanese patients aged 70 years or older
who had advanced NSCLC were randomized to receive either oral
erlotinib 150 mg (E) daily or oral vinorelbine 60 mg/m2 (V) on days
1 and 8 every 3 weeks.
Results: From February 2007 to July 2008, 116 patients were
enrolled and 113 were included in the intent-to-treat population: 57
patients in the E group and 56 patients in the V group. Objective
response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V
(p  0.0388). Median progression-free survival (PFS) was 4.57
months in E and 2.53 months in V (p  0.0287), with an 80.6%
increase in median PFS for E compared with V. Median survival
time was 11.67 months in E and 9.3 months in V (p  0.6975).
Toxicities were generally mild in both groups. Median PFS was
longest for epidermal growth factor receptor gene (EGFR)-mutated
patients in the E group, followed by EGFR-mutated patients in V,
EGFR wild type in E, and EGFR wild type in V (p  0.0034).
Overall survival was longer for EGFR-mutated patients than for
EGFR wild-type patients (p  0.0001).
Conclusions: Erlotinib is highly effective compared with oral vi-
norelbine in elderly, chemonaive, Taiwanese patients with NSCLC.
EGFR-mutated patients had better survival than those with EGFR
wild-type disease, regardless of the treatment received.
Key Words: Chemotherapy, Epidermal growth factor receptor, Non-
small-cell lung cancer, Targeted therapy, Tyrosine-kinase inhibitor.
(J Thorac Oncol. 2012;7: 412–418)
Lung cancer is typically a disease of elderly patients, withincidence peaking in the 70- to 80-year age group.1 An
analysis of the Surveillance, Epidemiology, and End Results
Database revealed that patients aged 70 years or older ac-
counted for 47% of all lung cancers.2 Despite the fact that
elderly patients account for the majority of the lung cancer
population, they are less likely to receive treatment than
younger patients.3,4 There is also an underrepresentation of
elderly patients (those aged 70 years or older) in clinical trials
of chemotherapy in non-small cell lung cancer (NSCLC).5
Thus, clinical trials specifically designed to investigate treat-
ments for elderly patients with NSCLC are important and
should be prioritized.6
Single-agent chemotherapy, with agents such as gem-
citabine or vinorelbine, is the typical option for advanced
NSCLC in treatment-naive elderly patients.6–8 Data analysis
suggests that outcomes in the fit elderly mirror results ob-
served in younger patients, although treatment-related toxic-
ity is generally worse.6,9,10 We recently published data show-
ing that combining vinorelbine with cisplatin produced a
better response rate and longer median time to disease pro-
gression versus vinorelbine alone in elderly patients with
NSCLC. This improvement in some efficacy endpoints, how-
ever, came with significantly increased toxicity and no sur-
vival advantage for the doublet.11
The efficacy of oral vinorelbine is similar to that of the
intravenous form, but the oral form is more convenient and
does not necessitate central venous access as required with a
Port-A implantation.12 Considering that all third-generation
agents (vinorelbine, gemcitabine, and taxanes) have similar
activity and efficacy in NSCLC, and single-agent vinorelbine
is considered a standard regimen for elderly patients with
NSCLC, oral vinorelbine may be more attractive and conve-
nient for many elderly patients and their healthcare providers,
because it is easy to use with no need for intravenous
injection.
Epidermal growth factor receptor (EGFR) tyrosine-
kinase inhibitors (TKIs), such as erlotinib and gefitinib, are
active agents against advanced NSCLC when given as sec-
ond- or third-line therapy, compared with best supportive
care or standard chemotherapy.6,13,14 Several trials have been
conducted with these agents in selected groups of chemona-
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ive patients with advanced NSCLC, such as elderly and poor
performance status (PS) patients, to address the concern
about treatment-related toxicities (TRTs) with conventional
chemotherapy.15–19 EGFR TKIs have also been investigated
in highly selected groups of chemonaive NSCLC patients
with the intention of selecting patients most likely to respond
to EGFR TKI therapy, such as those whose tumors harbor
activating EGFR mutations.20–22
EGFR TKIs are usually more effective in Asian
NSCLC patients, most likely due to the higher percentage of
activating EGFR mutations in this population, with favorable
objective response rates (ORRs), progression-free survival
(PFS), and overall survival (OS). Furthermore, the efficacy of
erlotinib is less influenced by histologic subtype, gender, and
smoking status, compared with gefitinib.13,23 On the basis of
these findings, we hypothesized that in elderly Taiwanese
patients with NSCLC, first-line therapy with erlotinib would
be at least as effective as chemotherapy with oral vinorelbine.
In this study, the primary end point was to compare the ORR
of erlotinib versus oral vinorelbine as first-line treatment in
elderly Taiwanese patients with NSCLC. We also examined
the role of activating EGFR mutations as a predictor of the
efficacy of erlotinib or vinorelbine.
METHODS
This study was an open-label, randomized, phase II trial
conducted according to guidelines for good clinical practice.
The study protocol was approved by the institutional review
board (NCT01196078). Patients with NSCLC who had never
received chemotherapy, targeted therapy, or hormonal ther-
apy were entered into the study after giving informed con-
sent. Eligibility criteria were a histologic or cytologic diag-
nosis of inoperable NSCLC; an Eastern Cooperative
Oncology Group (ECOG) PS of 0–3; measurable lesion(s);
no previous radiotherapy on measurable lesion(s); adequate
bone marrow reserve with a granulocyte count more than or
equal to 1500/mm3, platelets more than or equal to 100,000/
mm3, and hemoglobin more than or equal to 10 g/dL. Patients
with symptomatic or unstable brain metastases, inadequate
liver or renal function, or uncontrolled systemic disease were
excluded from the study.
The primary objective of the study was to compare
response rate between the two treatment arms. Secondary
objectives were to compare disease control rate (DCR), PFS,
OS, tolerability, and quality of life (QoL), as assessed using
the Functional Assessment of Cancer Therapy-Lung
(FACT-L) QoL instrument, between the two treatment arms.
Baseline evaluations included documentation of the
patient’s history and a physical examination. A complete
blood cell count, serum biochemistry profile, electrocardio-
gram, and computed tomography (CT) scan of the chest
(including the liver and adrenal glands) were also performed.
A whole-body bone scan and brain CT or magnetic resonance
imaging scan were performed as routine pretreatment evalu-
ations. Subsequent complete blood cell count and serum
biochemistry studies were performed every 3 weeks until
patients went off the study or completed treatment. An
additional complete blood cell count was performed on day 8
for the vinorelbine group (i.e. before the patients took oral
vinorelbine).
Eligible patients were randomized (stratified by histol-
ogy, smoking status [no, 100 lifetime cigarettes; yes, more
than or equal to 100 lifetime cigarettes regardless of current
smoking status], ECOG PS, and gender) to receive either oral
erlotinib 150 mg/d (E arm) or oral vinorelbine 60 mg/m2 on
days 1 and 8 of every 3-weekly cycle (V arm). The vinore-
lbine dose could increase to 80 mg/m2 beginning from cycle
2 provided the patient did not suffer from any more than or
equal to grade 2 toxicity.
Drug-related adverse events and toxicities were re-
corded, according to the Common Toxicity Criteria of the
National Cancer Institute version 3.0. Evaluation of response
was performed after two cycles of treatment, and every two
cycles thereafter until completion of six cycles. Best response
was assessed according to the RECIST version 1.0.24 Re-
sponding patients and those with stable disease continued
treatment until disease progression or completion of six
cycles. Patients could continue treatment beyond six cycles
provided their disease was controlled, and subsequent treat-
ment response evaluation was performed every four cycles.
This study was designed to enroll at least 53 eligible
patients in each arm. This calculation assumed that the true
ORR for the more effective treatment would be 10% higher
than for the other treatment. Assuming that the lower re-
sponse rate was 15% and the higher one was 25%, with a
power of 0.9 and a p value of 0.05, each treatment group
required 53 eligible patients (Simon phase II randomized trial
design).25 ORR and survival outcomes were analyzed using
an intent-to-treat (ITT) principle. The p value of the compar-
ison of differences in tumor response rates between the two
patient groups was determined by using logistic regression
analysis with consideration for multiple factors including
gender, ECOG PS, histology, and smoking status. PFS and
OS were analyzed using the Kaplan-Meier estimation method
with the log-rank test. Hazard ratios (HRs) were calculated
using the Cox proportional hazards model. PFS was calcu-
lated from the date of randomization to the date of first
documented progression or death from any cause. OS was
measured from the date of randomization until the date of
death or last follow-up. SAS v.8.2 software was used for
statistical analysis.
EGFR mutation analysis was performed with nucleo-
tide sequence analysis. The VarientSEQr Resequencing
Primer Set (Applied Biosystems, Foster City, CA) was se-
lected for mutational analysis of the tyrosine-kinase domain,
specifically exons 18–21 of the EGFR gene. DNA was
extracted, exons 18–21 were amplified, and uncloned poly-
merase chain reaction fragments were sequenced and ana-
lyzed in both sense and antisense directions for the presence
of heterozygous mutations. All sequence variants were con-
firmed by multiple independent polymerase chain reaction
amplifications, and forward and reverse sequencing reactions
were done. Chromatograms were analyzed using SeqScape
v2.1 Software (Applied Biosystems). Genomic DNA was
derived from formalin-fixed paraffin blocks for mutational
analysis of the EGFR coding sequence. Normal control DNA
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provided by the ABI company was used for wild-type con-
trol. Classical activating EGFR mutation was defined as
having an exon 19 deletion or exon 21 L858R point mutation.
RESULTS
Patient Characteristics
From February 2007 to July 2008, 116 patients were
enrolled in this study, comprising 58 patients in the E arm and
58 patients in the V arm. Two patients, one in each arm,
withdrew consent, did not receive any study medication and
were excluded from the ITT population. One patient in the V
arm had symptomatic brain metastases at baseline and was
also excluded from the ITT population; he was kept in the
safety analysis, however, because he had received one dose of
the study medication. Thus, the ITT population consisted of
113 patients: 57 in the E arm and 56 in the V arm. Figure 1
summarizes the subject disposition status (CONSORT dia-
gram). The clinical characteristics of the ITT population are
shown in Table 1. Males and smokers each accounted for
nearly 80% of the patients, and almost two-thirds of the
patients had adenocarcinoma. There was no statistical differ-
ence in the clinical characteristics of the two treatment
groups. Sixty patients (53.1%) had tumor tissue samples
available for EGFR mutation analysis.
Efficacy Analyses
The median number of cycles received was 5 in the E
arm and 3.5 in the V arm. After two cycles of treatment, 13
patients (22.8%) in the E arm and 5 (8.9%) in the V arm had
a partial response to treatment, which represented a statisti-
cally significant difference in ORR in favor of the E arm (p
0.0388). There was, however, no significant difference in the
response rates of the two treatment groups when performing
subgroup analyses, including gender, smoking status, PS,
histology, and EGFR mutation status. The DCR was 71.93%
in the E arm and 57.14% in the V arm (p 0.1061). After the
study treatment had failed, 29 patients in the E arm received
chemotherapy (15, vinorelbine alone; 7, vinorelbine plus
platinum; and 6, other chemotherapeutic agents) and 22
FIGURE 1. Disposition status of
116 enrolled elderly patients with
non-small cell lung cancer.
TABLE 1. Baseline Clinical Characteristics of the ITT
Population (n  113)
Characteristic
Erlotinib
(n  57)
Vinorelbine
(n  56) pa
Age, yr
Mean 78.1 77.8 0.7191
Median (range) 77 (70–90) 77 (70–90)
Sex, n (%)
Male 47 (82.5) 45 (80.4) 0.7743
Female 10 (17.5) 11 (19.6)
Smoking status, n (%)
Yes 45 (79) 44 (78.6) 0.961
No 12 (21) 12 (21.4)
Histology, n (%)
Squamous-cell carcinoma 19 (33.3) 13 (23.2) 0.2625
Adenocarcinoma 36 (63.2) 37 (66.1)
Other 2 (3.5) 6 (10.7)
Staging, n (%)
Unresectable stage IIIB 14 (24.6) 10 (17.9) 0.3836
Stage IV 43 (75.4) 46 (82.1)
ECOG PS, n (%)
0 2 (3.5) 2 (3.6) 0.8537
1 44 (77.2) 39 (69.6)
2 9 (15.8) 12 (21.4)
3 2 (3.5) 3 (5.4)
a The p value comparing difference between groups is computed using the t test,
Wilcoxon test, 2, or Fisher exact test.
ECOG, Eastern Cooperative Oncology Group; ITT, intent-to-treat; PS, performance
status.
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patients in the V arm received EGFR TKIs (either erlotinib or
gefitinib) (Figure 1).
Median PFS was 4.57 months in the E arm (eight
patients censored) and 2.53 months in the V arm (four
patients censored) (p  0.0287; Figure 2A). The HR was
0.6444 for E versus V (95% confidence interval 0.4325–
0.9601; p  0.0308). The 1-year PFS rate was 19.0% in the
E arm and 6.1% in the V arm. There was a trend toward
longer median PFS in the E arm than in the V arm when
performing subgroup analyses, including gender, histology,
smoking status, PS, and EGFR mutation status (Table 2). Cox
regression multivariate analysis for PFS, including treatment
with E or V, smoking or not, male or female, EGFR mutated
tumor or wild-type, adenocarcinoma or other NSCLC, and PS
less than or equal to 1 or more than or equal to 2, provided an
HR of 0.4633 for E treatment (p  0.0159), 3.4686 for
smoking (p  0.0107), 2.188 for male (p  0.1934), 0.39 for
EGFR-mutated tumor (p  0.0087), 0.8232 for adenocarci-
noma (p  0.5463), and 0.9219 for PS less than or equal to
1 (p  0.8151). Median OS was 11.67 months in the E arm
(14 patients censored) and 9.30 months in the V arm (14
patients censored) (p  0.6975; Figure 2B). The 1-year
survival rate was 48.8% in the E arm and 41.7% in the V arm.
After the study treatment had failed, 22 patients in the
E arm received cross-over vinorelbine-based salvage therapy
with a median OS of 17.3 months (four patients censored)
from the date of randomization into the study. Similarly, 22
patients in the V arm received EGFR TKI salvage therapy
with a median OS from randomization of 22.6 months (8
patients censored) (p  0.8925).
FIGURE 2. Survival status of intent-to-treat population
treated with erlotinib (n  57) or vinorelbine (n  56). A,
Progression-free survival (PFS): median PFS was 4.57 months
in the erlotinib arm (eight censored) and 2.53 months in the
vinorelbine arm (four censored) (p  0.0287). Hazard ratio
was 0.6444 for erlotinib treatment comparing vinorelbine
treatment (95% confidence interval: 0.4325–0.9601; p 
0.0308). The 1-year PFS was 19% in the erlotinib arm and
6.1% in the vinorelbine arm. B, Overall survival (OS): me-
dian OS was 11.67 months in the erlotinib arm (14 cen-
sored) and 9.3 months in the vinorelbine arm (14 censored)
(p  0.6975). The 1-year survival rate was 48.8% in the er-
lotinib arm and 41.7% in the vinorelbine arm.
TABLE 2. Subgroup Analyses of PFS by Clinical
Characteristics and EGFR Mutation Status
Treatment
p
Erlotinib Vinorelbine
n
Median
(mo) n
Median
(mo)
Sex
Male 47 4.07 42 2.5 0.1323
Female 10 8.4 11 8.87 0.1348
Histology
Adenocarcinoma 38 4.57 41 3 0.0464
Squamous
cell
18 4.07 12 1.47 0.1501
Other 1 1.23 3 1.47 0.0833
Smoking status
No 15 8.4 15 4.13 0.0223
Yes 42 3.83 41 2.47 0.3528
ECOG PS
0 2 9.63 2 1.53 0.4328
1 44 4.57 40 2.8 0.0152
2 9 1.37 11 1.87 0.6137
3 2 1.03 3 7.03 0.8864
EGFR mutation
status
Mutateda 9 8.4 15 3.97 0.2255
Wild type 21 3.83 15 1.47 0.0436
Unknown 27 5.07 26 2.17 0.073
a Included tumors with activating mutations of EGFR, specifically exon 19 dele-
tions or exon 21 L858R point mutations.
PFS, progression-free survival; EGFR, epidermal growth factor receptor gene;
ECOG, Eastern Cooperative Oncology Group; PS, performance status.
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Biomarker Analyses
Of the 60 patients whose tumors had known EGFR
mutation status, 24 had an activating EGFR mutation (9 in the
E arm and 15 in the V arm; 21 had exon 19 deletions and 3
had L858R mutations in exon 21), and 36 had wild-type
EGFR. Median PFS was highest in the EGFR-mutated sub-
group in the E arm (n 9, one censored, median 8.4 months),
followed by the EGFR-mutated subgroup in the V arm (n 
15, two censored, median 3.97 months), the EGFR wild-type
subgroup in the E arm (n  21, one censored, median 3.83
months), and the EGFR wild-type subgroup in the V arm
(n 15, zero censored, median 1.47 months) (Figure 3A; p
0.0034). In the unknown EGFR status group, median PFS
was longer if patients received E (n  27, six censored,
median 5.07 months) instead of V (n  26, two censored,
median 2.17 months) (p  0.073).
When patients in both arms were considered together,
median PFS was significantly prolonged in those whose
tumors had activating EGFR mutations (n  24, three cen-
sored, median 7.57 months), compared with EGFR wild type
(n  36, one censored, median 2.47 months) (p  0.0119).
OS was longer for the EGFR-mutated subgroup in both the E
arm (n  9, three censored, median 22.8 months) and the V
arm (n  15, nine censored, median 29.9 months), compared
with EGFR wild-type subgroups in both the E arm (n  21,
two censored, median 6.9 months) and the V arm (n  15,
zero censored, median 4.43 months) (Figure 3B, p 0.0001).
When the patients in both arms were considered to-
gether, OS was significantly longer for patients whose tumors
had activating EGFR mutations (n 24, 12 censored, median
33.6 months) versus EGFR wild type (n 36, two censored,
median 5.3 months) (p  0.0001).
Safety and Tolerability
One hundred fourteen patients received at least one
dose of study treatment. TRTs were generally mild, and the
majority of patients did not need any dose adjustment; there
was no toxicity-related death. The most frequent TRTs (in-
cidence rate more than or equal to 10%) in the E arm were
rash (64.91%), diarrhea (29.82%), and mouth ulceration
(14.04%); in the V arm, decreased appetite (26.32%), diar-
rhea (12.28%), vomiting (10.53%), and anorexia (10.53%)
were the most frequent TRTs. Skin rash, diarrhea, and mouth
ulceration occurred more frequently with E than with V (p 
0.05), while decreased appetite occurred more frequently in
the V arm than the E arm (p  0.05).
QoL
The FACT-L questionnaire contains four general sub-
scales, including physical well-being, social/family well-be-
ing, emotional well-being, functional well-being, and one
lung cancer symptom-specific subscale, the lung cancer sub-
scale. The FACT-L questionnaires were given to patients at
six assessment time points (cycles 1–6) and at the end of
treatment. Most FACT-L subscales showed no significant
change at the end of treatment for both treatment arms, except
that patients in the E arm had significantly better physical
well-being than patients in the V arm. Most patients in both
arms had stable pulmonary symptoms (lung cancer subscale)
at the end of treatment.
DISCUSSION
Kudoh et al.26 reported from Japan that intravenous
vinorelbine treatment (25 mg/m2 days 1 and 8, every 3 weeks,
FIGURE 3. Survival status of patients with epidermal
growth factor receptor gene (EGFR) mutation data available
(n  60). A, Progression-free survival (PFS): median PFS was
higher in the EGFR-mutated subgroup in the E arm (n  9,
one censored, median 8.4 months), followed by the EGFR-
mutated subgroup in the V arm (n  15, two censored, me-
dian 3.97 months), the EGFR wild-type subgroup in the E
arm (n  21, one censored, median 3.83 months), and the
EGFR wild-type subgroup in the V arm (n  15, zero cen-
sored, median 1.47 months) (p  0.0034). B, Overall sur-
vival (OS): median OS was longer in the EGFR-mutated sub-
group in the E arm (n  9, three censored, median 22.8
months) and the EGFR-mutated subgroup in the V arm (n 
15, nine censored, median 29.8 months), followed by the
EGFR wild-type subgroup in the E arm (n  21, two cen-
sored, median 6.9 months) and the EGFR wild-type sub-
group in the V arm (n  15, zero censored, median 4.43
months) (p  0.0001).
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the recommended dose in Japan) yielded a 3.1-month median
PFS, 9.9% response rate, and 36.7% 1-year survival rate in a
randomized phase III trial of treatment-naive elderly Japanese
patients with NSCLC. The starting dose of oral vinorelbine at
60 mg/m2 in this study was the equivalent of the 25 mg/m2
intravenous dose used in the Japanese study.12
In our study, median PFS was longer in patients who
received erlotinib treatment than vinorelbine; this difference
existed regardless of the patient’s EGFR mutation status
(mutated, wild type, or unknown). In addition, male patients,
current or former smokers, and those with squamous-cell
carcinoma also had numerically longer (although not statis-
tically significant) PFS with erlotinib versus vinorelbine (Ta-
ble 2). These results imply that erlotinib could be considered
as an effective first-line treatment for elderly patients with
NSCLC, irrespective of clinical or EGFR mutation status.
The treatment results in patients whose tumors had
EGFR mutations were similar to those of the IRESSA Pan-
Asia study, but the results in patients whose tumors were
EGFR wild-type differed between the two studies.22 Patients
with EGFR wild-type tumors had better PFS with erlotinib
than vinorelbine in our study, whereas in the IRESSA Pan-
Asia study, PFS was superior with paclitaxel plus carboplatin
versus gefitinib in the EGFR wild-type subgroup.22 Possible
reasons for this difference include superior efficacy of dou-
blet chemotherapy versus single-agent chemotherapy,27
greater potency of erlotinib compared with gefitinib, and the
different EGFR mutation detection methods used in the
studies.
In the study by Jackman et al.,15 in which 80 elderly
NSCLC patients were treated with erlotinib, a partial re-
sponse was noted in 10% of patients and the DCR was 51%
(Table 3). The 1-year survival rate of 46% for these erlotinib-
treated elderly patients was relatively similar to, or better
than, that of elderly patients treated with first-line chemother-
apy.7,11 In the study by Crino` et al.,17 elderly treatment-naive
NSCLC patients were treated with gefitinib or intravenous
vinorelbine. The ORR and DCR were 3.1 and 43.3%, respec-
tively, for patients receiving gefitinib. Median survival was
5.9 months, and the 1-year survival rate was 33.9% in
gefitinib-treated elderly patients. The ORR, median PFS, and
median OS in both the gefitinib and intravenous vinorelbine
arms were poorer than in our erlotinib and oral vinorelbine
arms, respectively (Table 3).
The better response of Asian patients to EGFR TKIs
and their longer survival has been documented repeatedly.
Median OS was shorter in Swinson et al.,16 in which elderly
NSCLC patients were treated with gefitinib. By contrast, in a
Japanese study of treatment-naive elderly NSCLC patients, in
which the majority were female (65%), had adenocarcinoma
(82%), and had never smoked (61%), treatment with gefitinib
produced a response rate of 25% and median OS of 10
months.19 The clinical characteristics of this Japanese study
are quite different from ours: our patients had higher propor-
tions of poor clinical characteristics, which is consistent with
the condition of general geriatric lung cancer patients. Of
course, it is difficult to compare these different studies,
because they had different patient populations with different
clinical characteristics and different EGFR mutation profiles.
However, based on limited small studies, it seems that erlo-
tinib had a similar or better effect in both White and Asian
unselected elderly NSCLC patients who received a first-line
EGFR TKI, in terms of PFS and OS, compared with gefitinib
(Table 3). In addition, oral vinorelbine had better results than
intravenous vinorelbine, when comparing our study with that
of Crino` et al.17
In conclusion, both oral agents are appropriate treat-
ment, but erlotinib is more highly effective than oral vinore-
lbine in elderly, chemonaive, Taiwanese patients with
NSCLC. Patients with activating EGFR mutation-positive
disease had better survival than those with EGFR wild-type
disease, irrespective of whether they received erlotinib or
vinorelbine.
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